Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2233-2240

  Marx, D ^a   Binder, C ^a   Meden, H ^a   Lenthe, T ^a   Ziemek, T ^a   Hiddemann, T ^a   Kuhn, W ^a   Schauer, A ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Apoptosis; Bax; bcl 2; Ovarian cancer; Prognosis

Indexed keywords

TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, ENDOMETRIOID; CYSTADENOMA, PAPILLARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MITOTIC INDEX; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TIME FACTORS;

EID: 0030749219     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Petterson F: Annual report on the results of treatment in gynecologic cancer. Int J Gynecol Obstet 36 (suppl.): 21, 1991.
2. Sorbe B, Frankendal B, Veress B: Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 59: 576-582, 1982.
3. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413-420, 1983.
4. Sigurdsson K, Alm P, Gullberg B: Prognostic factors in malignant epithelial tumors. Gynecol Oncol 15: 370-380, 1983.
5. Malkasian GC, Melton J, O'Brien PC, Greene MH: Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obst Gynecol 149: 274-284, 1984.
6. Meerpohl HG: Prognosefaktoren des Ovarialkarzinoms. Onkologie 8: 296-304, 1985.
7. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA: Ovarian carcinoma: a multivariative analysis of prognostic factors. Obstet Gynecol 65: 264-270, 1985.
8. Russel P: Common epithelial tumors of the ovary. In: Obstetrical and gynaecological Pathology, Vol.1.3rd edn. (Fox H, ed.). Edinburgh, Churchill Livingstone, 1987, pp 555-622.
9. Rath W, Meden H: The therapeutic concept in ovarian cancer. Med Klinik 86: 263-268, 1991.
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove S, Ulrich A, Press MF: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
11. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W, Schauer A: Overexpression of the oncogene c-erb-B2 in primary ovarian cancer: evaluation of the prognostic value in a cox proportional hazards multiple regression. Int J Gynecol Pathol 13: 45-53, 1994.
12. Meden H, Marx D, Raab T, Krohn M, Schauer A, Kuhn W: EGF-R and overexpression of the oncogene c-erbB2 in ovarian cancer: Immunohistochemical findings and prognostic value. J Obstet Gynaecol 21: 167-178, 1995.
13. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Woper JT, Dodge R, Clarke-Pearson DL, Marks P: Overexpressionof HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990.
14. Henriksen R, Strang P, Wilander E, Bδckstrωm T, Tribukait B, ÷berg K: p53 expression in epithelial ovarian neoplasms: Relationship to clinical and pathological parameters. Ki-67 expression and flow cytometry. Gynecol Oncol 53: 301-306, 1994.
15. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 606-619, 1993.
16. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka L, Mao X, Nunez G, Thompson CB: Bcl-X, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993.
17. Yang E, Tha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ: Bad, a heterodimer partner for Bcl-XI and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
18. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW: mcl1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to bcl-2. Proc Natl Acad Sci USA 90: 3512-3516, 1993.
19. Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC: Induction of apoptosis by the Bcl-2 homologe Bak. Nature 374: 733-736, 1995.
20. Hunter JJ, Parslow TG: A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis. J Bio Chem 271: 8521-8524, 1996
21. Yang E, Korsmeyer J: Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 88: 386-401, 1996
22. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W: Bcl-2 prorein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 6: 1005-1010, 1995
23. Joenssu H, Pylkkδnen L, Toikkanen S: Bcl-2 protein expression and long-term-survival in breast cancer. Am J Pathol 145: 1191-1198, 1994
24. Doglioni C, DeiTos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G: The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular refernce to oestrogen receptor status. Virchows Arch 424: 47-51, 1994.
25. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor-receptor-negative tumors and in situ cancers. Br J Cancer 69: 135-139, 1994.
26. Hellemanns P, Van Dam PA, Weyler J, van Oosterom AT, Buytaert P, van Mark E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360, 1995.
27. Gee J, Robertson J, Ellis IO, Willscher P, McClelland RA, Hoyle HB, Kyme R, Finley P, Blamey RW, Nicholson RI: Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994.
28. Henriksen R, Wilander E, Öberg K: Expression and prognostic significance of Bcl-2 in ovarian tumors. Br J Cancer 72: 1324-1329, 1995.
29. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, Lohrs U: bcl-2 expression, p53 accumulation, and apoptosis in ovarian cancer. Am J Clin Pathol 105: 241-249, 1996.
30. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184, 1996.
31. Binder C, Marx D, Binder L, Schauer A, Hiddemann W: Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer. Ann Oncol 7: 129-133, 1996.
32. Serov SF, Scully RE, Sobin LH: Histological typing of ovarian tumors. WHO International histological classification of tumors 9: 37-42, 1973.
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-8023, 1958.
34. Marx D, Meden H, Brune T, Kron M, Korabiowska M, Kuhn W, Schauer A: Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res 17: in press, 1997.
35. Tsujimoto Y, Gorham JJC, Jaffe E, Croce CM: The t(14;18) chromosome translocations involved in B-cell neoplasm result from mistakes in VDJ joining. Science 299: 1390-1393, 1985.
36. Ngan BJ, Chen-Levy Z, Weiss LM, Warnke RA, Clearly ML: Expression in non-Hodgkin¥s lymphoma of the bcl-2 protein associated with the t(14:18) chromosomal translocation. New Engl J Med 318: 1638-1644, 1988.
37. Hockenhery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 protein is topo graphically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991
38. Pezella F, Turley H, Kuzu LI, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY: Bcl-2 protein in non-small cell lung carcinoma. New Engl J Med 329: 690-694, 1993.
39. Hague A, Moorghen M, Hicks D, Chapmen M, Paraskeva C: Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 9: 3367-3370, 1994.
40. Pietenpol JA, Papadopoulus N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B: Paradoxical inhibition of solid tumor cell growth by Bcl-2. Cancer 54: 3714-3717, 1994.
41. Miyashita T, Harigai M, Hanada M, Reed JC: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 5501-5507, 1994.
42. Miyashita T, Reed J: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.